To the content
4 . 2017

Efficacy of antiviral treatment of chronic hepatitis C in patients with HCV/HIV coinfection in the comparative aspect

Abstract

The study included 77 patients with HCV/HIV coinfection: the first group (n=59) who received pegylated interferon alpha 2a (Peg-IFN-a2a) (at a dose of 180 mcg/week) and ribavirin (dose determined in depending on the HCV genotype) for 48 weeks, and the second consisted of 18 patients who were prescribed standard IFN-alpha 2b (St-IFN-a2b) 5 million IU with a daily regimen of administration of the first 24 weeks, then every other day up to 48 weeks in combination with ribavirin (10-15 mg/ kg/day).Efficiency of therapy with St-IFN-a2b and Peg-IFN-a2a in combination with ribavirin in HCV/HIV coinfection is comparabLe to the high frequency of achieving SVR in patients with CC genotype rs12979860 (76 and 78%) and the reLapse rate was 9.8 and 11.1% in the respective groups.

Keywords:HCV-infection, HCV/HIV ^infection, interferon-alpha

Infectious Diseases: News, Opinions, Training. 2017; (4): 51-56.
DOI: 10.24411/2305-3496-2017-00068


All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»